This study is testing a medicine called tildrakizumab for people with psoriatic arthritis, a joint disease often associated with the skin condition psoriasis. The study compares tildrakizumab with a placebo, which is a treatment that doesn't contain the active medicine. This study is Phase III, meaning it is close to being approved for general use if proven safe and effective. Participants will be randomly assigned to different groups and not know if they are receiving the real medicine or the placebo. Key points to consider:

• Duration: The study lasts until Week 24, with several visits required.
• Eligibility: Participants must be 18 or older, have tried other treatments, and meet specific health criteria.
• Risks: Participants with certain infections or health conditions, or those not using birth control (if needed), cannot join.

Participants should be ready to commit to all study procedures and visits. For any concerns or questions, talk to your doctor or the study coordinator.